Aptamer Group PLC Ordinary Shares (APTA)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.75p

Buy

0.80p

arrow-down-0.025p (-3.12%)

Prices updated at 12 Dec 2025, 16:15 GMT

Prices minimum 15 mins delay

Prices in GBX

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Adam Hargreaves

CEO

Dr. Arron Craig Tolley

Most recent earnings

30 Jun 2025

Fiscal year end

30 Jun 2025

Employees

31

Head office

Innovation Way

York

United Kingdom

YO10 5BR

+44 1904217404

info@aptamergroup.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Adam Hargreaves Non-Executive Director, Chairman	-
Mr. Timothy James Sykes Non-Executive Director	-
Dr. David Harry John Bunka Executive Director, Chief Scientific Officer	-
Mr. Andrew Rapson Executive Director, Chief Financial Officer and Company Secretary	-
Dr. Arron Craig Tolley Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Crux Asset Management Limited	82,368,805
TM Oberon UK Core Fund	45,952,139
TM Oberon UK Smaller Companies Fund	36,416,666
TM Oberon UK Special Situations Fund	16,931,626

Director dealings

Date chevron-l-regular chevron-r-regular	Action
08 Sep 2025	Purchase
28 Jul 2025	Purchase
03 Feb 2025	Purchase
13 Jan 2025	Purchase
19 Dec 2024	Purchase
16 Dec 2024	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.